ICU Recovery in Australian Patients
Launched by AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE RESEARCH CENTRE · Aug 25, 2014
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
The ICU Recovery program will measure psychological, functional and cognitive function and quality of life with health economic outcomes in critically ill patients 6 months after ICU admission. The initial pilot study will determine feasibility of the patient outcomes and measurement methods used. The study will consist of patients from three (3) Monash Partners ICUs (2 public and 1 private) as well as The Austin Hospital ICU. 10,000 ICU patients are managed by Monash Partners Academic Health Science Centre (MPAHSC) public and private hospitals each year, of which in the region of 8,500 pat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ICU patients who have been invasively mechanically ventilated for over 24 hours
- Exclusion Criteria:
- • Patients aged less than 18 years old
- • A proven or suspected acute primary brain process that is likely to result in global impairment of conscious level or cognition (e.g. traumatic brain injury, subarachnoid haemorrhage, stroke or hypoxic brain injury after cardiac arrest)
- • Second or subsequent admission to ICU during a single hospital admission
- • Death is deemed imminent and inevitable
- • Participants who do not speak English
About Australian And New Zealand Intensive Care Research Centre
The Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) is a leading research organization dedicated to improving outcomes in critically ill patients through innovative clinical trials and research initiatives. Based at Monash University, the Centre fosters collaborative partnerships among clinicians, researchers, and institutions across Australia and New Zealand. Its focus on evidence-based practice and translational research aims to enhance the quality of intensive care, drive advancements in treatment protocols, and ultimately improve patient care in the intensive care unit (ICU) setting. ANZIC-RC is committed to addressing key challenges in critical care medicine, ensuring that findings from its trials contribute to better health outcomes and inform clinical guidelines globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Malvern, Victoria, Australia
Clayton, Victoria, Australia
Richmond, Victoria, Australia
Heidelberg, Victoria, Australia
Patients applied
Trial Officials
Carol Hodgson, PhD MRes
Principal Investigator
ANZIC-RC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials